Understanding how microglia affect glaucoma
Official title: Dissecting the complex role of microglia states in glaucoma
Funded at University of Rochester · NIH-11086080 · Data updated 2026-11-12
This study is looking at how certain immune cells in the brain, called microglia, might affect the damage to vision caused by glaucoma, with the hope of finding new ways to help protect your eyesight beyond just lowering eye pressure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | June 1, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $650,978 |
| NIH project number | 5R01EY035093-03 |
| Project ID | NIH-11086080 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with glaucoma, particularly those experiencing vision loss.
✕Less likely to help
Patients with glaucoma who are not experiencing any symptoms or vision loss may not benefit from this research.
What this research studies
This research investigates the role of microglia, a type of immune cell in the brain, in the development and progression of glaucoma, a common age-related eye disease that leads to vision loss. The study aims to uncover the molecular mechanisms by which microglia contribute to the death of retinal ganglion cells, which are crucial for vision. By utilizing advanced sequencing technologies, researchers will explore the different states of microglia and how these states may either protect or harm retinal cells. This research could lead to new therapeutic strategies that go beyond current treatments focused solely on lowering eye pressure.
Why it matters
Potential benefit: If successful, this research could lead to the development of neuroprotective treatments for glaucoma, potentially preserving vision for many patients.
How similar studies have gone: Previous research has shown that targeting microglial responses can be beneficial in other neurodegenerative diseases, suggesting a promising avenue for glaucoma treatment.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Libby, Richard T — University of Rochester
- Study coordinator: Libby, Richard T
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Comparing tube positions in glaucoma implants to protect corneal cells
This trial compares two tube placements for glaucoma drainage implants to see which better protects corneal cells and controls eye pressure in people with uncontrolled glaucoma.
-
Automated topographic test for glaucoma detection and progression
A new automated method uses topographic structure-function mapping to help diagnose glaucoma earlier and track its progression in patients.
-
Using AI on eye scans and genes to predict glaucoma risk
This project uses artificial intelligence on eye scans, vision tests, and genetic information to find people most likely to develop or have worsening glaucoma.
-
AI-based glaucoma screening in community health centers
A new, easy-to-use AI screening approach will be tested in federally funded health centers to help identify people at risk for glaucoma, especially in communities with higher risk.
-
Understanding how glaucoma genes control eye cell function
A long-term research project will study how genetic factors affect eye cells in adults with glaucoma to uncover new ideas for protecting vision.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.